UC-associated autoantibodies to αvβ6 inhibit mucosal TGFβ activation and predispose to intestinal inflammation
Authors:
Preprint
Abstract
Ulcerative colitis (UC) is characterized by epithelial barrier dysfunction and dysregulated mucosal immune responses; however, the mechanisms driving disease onset remain poorly defined. Autoantibodies against the epithelial-restricted integrin αvβ6 are a highly specific biomarker of UC that can precede clinical diagnosis by up to 10 years. Because αvβ6 activates TGFβ at epithelial surfaces, we hypothesized that UC-associated αvβ6 autoantibodies inhibit mucosal TGFβ activation and disrupt epithelial homeostasis. We showed that αvβ6 autoantibodies were enriched in UC and that IgG from autoantibody-positive individuals inhibited αvβ6–dependent activation of TGFβ. αvβ6 blockade dampened TGFβ signaling and altered differentiation–associated gene programs in human intestinal epithelial cells. In mice, deletion of αv caused expansion of inflammation-associated goblet cells in the colon and changes in intestinal immune cells. Using a novel mouse model, we showed that αvβ6-specific autoantibody disrupted epithelial–immune crosstalk and increased susceptibility to DSS colitis. Together, these findings establish anti-αvβ6 autoantibodies as active inhibitors of epithelial TGFβ signaling, constituting a de facto anti-cytokine response, rather than passive biomarkers. By linking preclinical seropositivity to impaired epithelial signaling and heightened susceptibility to colitis, this work identifies epithelial αvβ6–dependent TGFβ activation as a pathway that may be leveraged to modify disease risk or limit disease severity. One Sentence Summary: UC-associated autoantibodies impair epithelial TGFβ activation, alter mucosal homeostasis, and predispose to colitis.Keywords
Funding Information
- National Institutes of Health (R01DK136071)
- National Institutes of Health (R21AI171921)
- McCaw Family Foundation
This publication has 82 references indexed in Scilit:
- Current and Emerging Autoantibodies in Ulcerative ColitisEuropean Journal of Immunology, 2025
- Anti-integrin αvβ6 antibody as a biomarker for diagnosing ulcerative colitis: a nationwide multicenter validation studyJournal of Gastroenterology, 2024
- Anti-integrin αvβ6 autoantibody in primary sclerosing cholangitis: a Japanese nationwide studyJournal of Gastroenterology, 2024
- Anti-integrin αvβ6 Autoantibodies Are Increased in Primary Sclerosing Cholangitis Patients With Concomitant Inflammatory Bowel Disease and Correlate With Liver Disease SeverityClinical Gastroenterology and Hepatology, 2024
- Dynamic allostery drives autocrine and paracrine TGF-β signalingCell, 2024
- Diagnostic value of anti-integrin αvβ6 antibodies in ulcerative colitisDigestive and Liver Disease, 2023
- Anti-integrin αvβ6 autoantibodies in patients with primary sclerosing cholangitisJournal of Gastroenterology, 2023
- Intra- and Inter-cellular Rewiring of the Human Colon during Ulcerative ColitisCell, 2019
- Genetic variants of SMAD2/3/4/7 are associated with susceptibility to ulcerative colitis in a Japanese genetic backgroundImmunology Letters, 2019
- Integrin-mediated activation of latent transforming growth factor βCancer and Metastasis Reviews, 2005